Maxim Group Maintains Their Buy Rating on OncoSec Medical (ONCS)

By Jason Carr

Maxim Group analyst Jason McCarthy maintained a Buy rating on OncoSec Medical (ONCSResearch Report) today and set a price target of $5. The company’s shares opened today at $0.59, close to its 52-week low of $0.42.

McCarthy observed:

“OncoSec announced that TAVO (DNA-based IL-12) has received ‘Advanced Therapy Medicinal Product (ATMP) classification in Europe for treatment of refractory metastatic melanoma. With this classification, TAVO could have a potential accelerated approval pathway.”

According to TipRanks.com, McCarthy has currently no stars on a ranking scale of 0-5 stars, with an average return of -7.3% and a 30.3% success rate. McCarthy covers the Healthcare sector, focusing on stocks such as SELLAS Life Sciences Group Inc, ContraVir Pharmaceuticals Inc, and Adial Pharmaceuticals Inc.

Currently, the analyst consensus on OncoSec Medical is a Moderate Buy with an average price target of $5.

See today’s analyst top recommended stocks >>

The company has a one-year high of $2.21 and a one-year low of $0.42. Currently, OncoSec Medical has an average volume of 517.8K.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

OncoSec Medical, Inc. is a biotechnology company, which engages in designing, developing, and commercializing therapies for the treatment of cancer. Its lead product candidate, ImmunoPulse IL-12, uses an electroporation device, with the aim of reversing the immunosuppressive microenvironment in the treated tumor.